Patent 8685998
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-flash
No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.
Cases on file (4)
Group view →Specific litigation cases in our database that name US patent 8685998. The free-form analysis below may also discuss cases beyond this list.
- Veloxis Pharmaceuticals AS v. Zydus Cadila et al.filed Apr 23, 20261:26-cv-00467Delaware District CourtOpen
Defendants: Zydus Cadila and Zydus Lifesciences Ltd
Other patents asserted: 11419823, 10864199, 8664239, 11123331, 12403095, 10166190, 11110081, 12083103, 9549918
The accused products are the 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets sold under the brand name ENVARSUS XR.
- Veloxis Pharmaceuticals, Inc. v. Glenmark Pharms. Inc.filed Apr 14, 20251:25-cv-00458District Court, DelawareOngoing
Defendants: Glenmark Pharms. Inc.
- Veloxis Pharmaceuticals, Inc. v. Alkem Labs. Ltd.filed Jul 3, 20241:24-cv-00784District Court, DelawareOngoing
Defendants: Alkem Labs. Ltd.
- 1:22-cv-00909District Court, DelawareOngoing
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
U.S. Patent No. 8,685,998 has been involved in multiple patent litigations. These cases generally appear to be related to Abbreviated New Drug Applications (ANDA) filings, as is common for pharmaceutical patents, and involve Veloxis Pharmaceuticals Inc. (the current assignee) as a plaintiff.
Here's a summary of the known litigation:
Case 1:
- Plaintiff(s): Veloxis Pharmaceuticals, Inc.
- Defendant(s): Alkem Labs. Ltd.
- Jurisdiction: District Court, Delaware
- Case Number: 1:24-cv-00784 or 24-0784 (D. Del.)
- Filing Date: July 3, 2024
- Outcome/Status: Ongoing (as of April 26, 2026).
Case 2:
- Plaintiff(s): Veloxis Pharmaceuticals, Inc.
- Defendant(s): Not explicitly stated in the provided snippet, but likely an ANDA filer.
- Jurisdiction: District Court, Delaware
- Case Number: 1:22-cv-00909
- Filing Date: Not explicitly stated, but the case number suggests 2022.
- Outcome/Status: Ongoing (as of April 26, 2026).
Case 3:
- Plaintiff(s): Veloxis Pharmaceuticals, Inc.
- Defendant(s): Not explicitly stated in the provided snippet, but likely an ANDA filer.
- Jurisdiction: District Court, Delaware
- Case Number: 1:24-cv-00726
- Filing Date: Not explicitly stated, but the case number suggests 2024.
- Outcome/Status: Ongoing (as of April 26, 2026).
Case 4:
- Plaintiff(s): Veloxis Pharmaceuticals, Inc.
- Defendant(s): Glenmark Pharms. Inc.
- Jurisdiction: District Court, Delaware
- Case Number: 1:25-cv-00458 or 25-0458 (D. Del.)
- Filing Date: Not explicitly stated for 1:25-cv-00458, but a related entry (25-0458 D. Del.) indicates April 14, 2025.
- Outcome/Status: Ongoing (as of April 26, 2026).
The litigation data indicates that these cases are filed in the Delaware District Court and are often related to the drug Envarsus XR® (tacrolimus extended-release tablets).
Generated 5/31/2026, 12:46:30 AM